Omalizumab in the therapy of pediatric asthma

Research output: Contribution to journalReview article

Abstract

Background: Eosinophilic asthma is driven by Th2 immune response and is usually characterized by the increase of total serum IgE levels and/or specific IgE that express single or multiple allergen sensitization. In such an immuno-pathological background, the anti-IgE therapy, namely omalizumab, found its main clinical utility and recommendation to treat severe asthma. Objective: In this mini-review, we summarized the most relevant immuno-pathological and clinical evidences supporting the use of omalizumab in the therapy of pediatric asthma. Furthermore, we provided the main practical points for its use in the therapeutic management of asthmatic children. Method: Through the binding of serum free IgE, omalizumab impairs not only the effector phase of IgE-mediated asthma, but also affects the IgE biology and the related immune response, globally. Here, the history of omalizaumab has been shortly reviewed from its preclinical development to its clinical validation in pediatric asthma. Thus, recent patents regarding anti-IgE therapy have been discussed. Conclusion: Omalizumab significantly improved the clinical management of severe and uncontrolled pediatric asthma; however, pre-treament IgE levels limited the use of omalizumab in some patients and the cost of the therapy is still relevant. Moreover, the optimal duration of the treatment with omalizumab in children has to be determined. Finally, the recent generation of a mutant IgE-Fc fragment being resistant to omalizumab binding might open further therapeutic applications, in addition to second generation anti-IgE antibodies.

Original languageEnglish
Pages (from-to)103-109
Number of pages7
JournalRecent Patents on Inflammation and Allergy Drug Discovery
Volume12
Issue number2
DOIs
Publication statusPublished - Jan 1 2018
Externally publishedYes

Fingerprint

Immunoglobulin E
Asthma
Pediatrics
Therapeutics
Immunoglobulin Fc Fragments
Patents
Therapeutic Uses
Omalizumab
Serum
Allergens
History
Costs and Cost Analysis
anti-IgE antibodies

Keywords

  • Anti-igE therapy
  • IgE biology
  • IgE variants
  • Omalizumab
  • Pediatric asthma

ASJC Scopus subject areas

  • Immunology and Allergy
  • Drug Discovery

Cite this

Omalizumab in the therapy of pediatric asthma. / Poddighe, Dimitri; Brambilla, Ilaria; Licari, Amelia; Marseglia, Gian L.

In: Recent Patents on Inflammation and Allergy Drug Discovery, Vol. 12, No. 2, 01.01.2018, p. 103-109.

Research output: Contribution to journalReview article

@article{9b952f302bc24440ab4bc1b40d36ac0a,
title = "Omalizumab in the therapy of pediatric asthma",
abstract = "Background: Eosinophilic asthma is driven by Th2 immune response and is usually characterized by the increase of total serum IgE levels and/or specific IgE that express single or multiple allergen sensitization. In such an immuno-pathological background, the anti-IgE therapy, namely omalizumab, found its main clinical utility and recommendation to treat severe asthma. Objective: In this mini-review, we summarized the most relevant immuno-pathological and clinical evidences supporting the use of omalizumab in the therapy of pediatric asthma. Furthermore, we provided the main practical points for its use in the therapeutic management of asthmatic children. Method: Through the binding of serum free IgE, omalizumab impairs not only the effector phase of IgE-mediated asthma, but also affects the IgE biology and the related immune response, globally. Here, the history of omalizaumab has been shortly reviewed from its preclinical development to its clinical validation in pediatric asthma. Thus, recent patents regarding anti-IgE therapy have been discussed. Conclusion: Omalizumab significantly improved the clinical management of severe and uncontrolled pediatric asthma; however, pre-treament IgE levels limited the use of omalizumab in some patients and the cost of the therapy is still relevant. Moreover, the optimal duration of the treatment with omalizumab in children has to be determined. Finally, the recent generation of a mutant IgE-Fc fragment being resistant to omalizumab binding might open further therapeutic applications, in addition to second generation anti-IgE antibodies.",
keywords = "Anti-igE therapy, IgE biology, IgE variants, Omalizumab, Pediatric asthma",
author = "Dimitri Poddighe and Ilaria Brambilla and Amelia Licari and Marseglia, {Gian L.}",
year = "2018",
month = "1",
day = "1",
doi = "10.2174/1872213X12666180430161351",
language = "English",
volume = "12",
pages = "103--109",
journal = "Recent Patents on Inflammation and Allergy Drug Discovery",
issn = "1872-213X",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - Omalizumab in the therapy of pediatric asthma

AU - Poddighe, Dimitri

AU - Brambilla, Ilaria

AU - Licari, Amelia

AU - Marseglia, Gian L.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Eosinophilic asthma is driven by Th2 immune response and is usually characterized by the increase of total serum IgE levels and/or specific IgE that express single or multiple allergen sensitization. In such an immuno-pathological background, the anti-IgE therapy, namely omalizumab, found its main clinical utility and recommendation to treat severe asthma. Objective: In this mini-review, we summarized the most relevant immuno-pathological and clinical evidences supporting the use of omalizumab in the therapy of pediatric asthma. Furthermore, we provided the main practical points for its use in the therapeutic management of asthmatic children. Method: Through the binding of serum free IgE, omalizumab impairs not only the effector phase of IgE-mediated asthma, but also affects the IgE biology and the related immune response, globally. Here, the history of omalizaumab has been shortly reviewed from its preclinical development to its clinical validation in pediatric asthma. Thus, recent patents regarding anti-IgE therapy have been discussed. Conclusion: Omalizumab significantly improved the clinical management of severe and uncontrolled pediatric asthma; however, pre-treament IgE levels limited the use of omalizumab in some patients and the cost of the therapy is still relevant. Moreover, the optimal duration of the treatment with omalizumab in children has to be determined. Finally, the recent generation of a mutant IgE-Fc fragment being resistant to omalizumab binding might open further therapeutic applications, in addition to second generation anti-IgE antibodies.

AB - Background: Eosinophilic asthma is driven by Th2 immune response and is usually characterized by the increase of total serum IgE levels and/or specific IgE that express single or multiple allergen sensitization. In such an immuno-pathological background, the anti-IgE therapy, namely omalizumab, found its main clinical utility and recommendation to treat severe asthma. Objective: In this mini-review, we summarized the most relevant immuno-pathological and clinical evidences supporting the use of omalizumab in the therapy of pediatric asthma. Furthermore, we provided the main practical points for its use in the therapeutic management of asthmatic children. Method: Through the binding of serum free IgE, omalizumab impairs not only the effector phase of IgE-mediated asthma, but also affects the IgE biology and the related immune response, globally. Here, the history of omalizaumab has been shortly reviewed from its preclinical development to its clinical validation in pediatric asthma. Thus, recent patents regarding anti-IgE therapy have been discussed. Conclusion: Omalizumab significantly improved the clinical management of severe and uncontrolled pediatric asthma; however, pre-treament IgE levels limited the use of omalizumab in some patients and the cost of the therapy is still relevant. Moreover, the optimal duration of the treatment with omalizumab in children has to be determined. Finally, the recent generation of a mutant IgE-Fc fragment being resistant to omalizumab binding might open further therapeutic applications, in addition to second generation anti-IgE antibodies.

KW - Anti-igE therapy

KW - IgE biology

KW - IgE variants

KW - Omalizumab

KW - Pediatric asthma

UR - http://www.scopus.com/inward/record.url?scp=85053830703&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053830703&partnerID=8YFLogxK

U2 - 10.2174/1872213X12666180430161351

DO - 10.2174/1872213X12666180430161351

M3 - Review article

AN - SCOPUS:85053830703

VL - 12

SP - 103

EP - 109

JO - Recent Patents on Inflammation and Allergy Drug Discovery

JF - Recent Patents on Inflammation and Allergy Drug Discovery

SN - 1872-213X

IS - 2

ER -